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Introduction
A workshop (Antimicrobial Resistance in 
the Environment: Assessing and Managing 
Effects of Anthropogenic Activities), held in 
March 2012 in Québec, Canada, focused on 
anti biotic resistance in the environment and 
approaches to assessing and managing effects 
of anthropogenic activities. The human health 
concern was identified as environmentally 
derived antibiotic­resistant bacteria (ARB) 
that may adversely affect human health (e.g., 
reduced efficacy in clinical anti biotic use, 
more serious or prolonged infection) either 
by direct exposure of patients to antibiotic­
resistant pathogen(s) or by exposure of patients 
to resistance determinants and subsequent 
horizontal gene transfer (HGT) to bacterial 
pathogen(s) on or within a human host, as 
conceptualized in Figure 1. ARB hazards 
develop in the environment as a result of direct 
uptake of antibiotic­resistant genes (ARG) 
via various mechanisms (e.g., mobile genetic 
elements such as plasmids, integrons, gene 
cassettes, or transposons) and/or proliferate 
under environmental selection caused by anti­
biotics and coselecting agents such as biocides, 
toxic metals, and nanomaterial stressors 
(Qiu et al. 2012; Taylor et al. 2011), or by 
gene mutations (Gillings and Stokes 2012). 
Depending on the presence of recipient 
bacteria, these processes generate either 
environmental antibiotic­resistant bacteria 
(eARB) or pathogens with antibiotic­resistance 
(pARB) (Figure 1).
Human health risk assessment (HHRA) 
is the process used to estimate the nature 
and probability of adverse health effects in 
humans who may be exposed to hazards in 
contaminated environmental media, now or 
in the future [U.S. Environmental Protection 
Agency (EPA) 2012]. In this review we focus 
on how to apply HHRA to the risk of infec­
tions with pathogenic ARB because they are 
an increasing cause of morbidity and mor­
tality, particularly in developing regions 
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Methods: The authors participated in a workshop held 4–8 March 2012 in Québec, Canada, to 
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exposure assessment (unrelated to food), and dose response to characterize risks that may improve 
antibiotic-resistance management options.
discussion: Various novel aspects to traditional risk assessments were identified to enable an 
assessment of environmental antibiotic resistance. These include a) accounting for an added selec-
tive pressure on the environmental resistome that, over time, allows for development of antibiotic-
resistant bacteria (ARB); b) identifying and describing rates of horizontal gene transfer (HGT) in 
the relevant environmental “hot spot” compartments; and c) modifying traditional dose–response 
approaches to address doses of ARB for various health outcomes and pathways.
conclusions: We propose that environmental aspects of antibiotic-resistance development be 
included in the processes of any HHRA addressing ARB. Because of limited available data, a multi-
criteria decision analysis approach would be a useful way to undertake an HHRA of environmental 
antibiotic resistance that informs risk managers. 
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(Grundmann et al. 2011). An antimicrobial­
resistant micro organism has the ability to mul­
tiply or persist in the presence of an increased 
level of an anti microbial agent compared with 
a susceptible counter part of the same species. 
For this review, we limited the resistant group 
of micro organisms to bacteria and therefore 
to anti biotic resistance, an area in which the 
term “antibiotic” is used synonymously with 
“antibacterial.” It is important to understand 
the contribution that the environment has on 
the development of resistance in both human 
and animal pathogens because therapeutic­
resistant infections may lead to longer hos­
pitalization, longer treatment time, failure of 
treatment therapy, and the need for treatment 
with more toxic or costly antibiotics, as well as 
an increased likelihood of death.
A vast amount of work has been under­
taken to understand the contribution and roles 
played by hospital and community settings in 
the dissemination and maintenance of ARB 
infections in humans. A particular area of focus 
in terms of exposure in a community setting 
has been anti biotic use in livestock produc­
tion and the presence of eARB and pARB in 
food of animal origin. In 2011, the Codex 
Alimentarius Commission [established in 1963 
by the Food and Agriculture Organization of 
the United Nations (FAO) and the World 
Health Organization (WHO) to harmonize 
international food standards, guidelines, and 
codes of practice to protect the health of con­
sumers and ensure fair trade practices in the 
food trade] released guidelines on processes 
and methodologies for applying risk analy­
sis methods to foodborne anti microbial resis­
tance related to the use of anti microbials in 
veterinary medicine and agriculture (Codex 
Alimentarius Commission 2011). 
Other sources of anti biotics and other 
anti microbials in the environment are human 
sewage (Dolejska et al. 2011), intensive ani­
mal husbandry, and waste from the manu­
facture of pharmaceuticals (Larsson et al. 
2007). The environmental consequences 
from the use and release of anti biotics from 
various sources (Kümmerer 2009a, 2009b) 
and the HGT of antibiotic­resistance genes 
(ARG) between indigenous environmental 
and pathogenic bacteria and their resistance 
determinants (Börjesson et al. 2009; Chagas 
et al. 2011; Chen et al. 2011; Cummings 
et al. 2011; Forsberg et al. 2012; Gao et al. 
2012; Qiu et al. 2012) has yet to be quanti­
fied, but is of global concern (Finley et al. 
2013; WHO 2012a). The genetic elements 
encoding for the ability of micro organisms 
to withstand the effects of an anti microbial 
agent are located either chromosomally or 
extra chromosomally and may be associated 
with mobile genetic elements such as plas­
mids, integrons, gene cassettes, or transpo­
sons, thereby enabling horizontal and vertical 
transmission from resistant to previously 
susceptible strains. From an HHRA point 
of view, the emergence of ARB in source 
and drinking water (De Boeck et al. 2012; 
Isozumi et al. 2012; Shi et al. 2013) further 
highlights the need to place these emerging 
environmental risks in perspective. Yet, assess­
ing the range of environmental contribu­
tions to anti biotic resistance may not only be 
complicated by lack of quantitative data but 
also by the need to coordinate efforts across 
different agencies that may have jurisdiction 
over environmental risks versus human and 
animal health.
A key consideration for ARB develop­
ment in the environment is that resistance 
genes can be present due to natural occur­
rence (D’Costa et al. 2011). Further, the 
use of anti microbials in crops, animals, and 
humans provides a continued entry of anti­
biotics to the environment, along with pos­
sible novel genes and ARB. A summary of the 
fate, transport, and persistence of antibiotics 
and resistance genes after land application 
of waste from food animals that received 
antibiotics or following outflow to surface 
water from sewage treatment has emphasized 
the need to better understand the environ­
mental mechanisms of genetic selection and 
gene acquisition as well as the dynamics of 
resistance genes (resistome) and their bacte­
rial hosts (Chee­Sanford et al. 2009; Crtryn 
2013). For example, the presence of anti­
biotic residues in water from pharma ceuti cal 
manufacturers in certain parts of the world 
(Fick et al. 2009), ponds receiving intensive 
animal wastes (Barkovskii et al. 2012), aqua­
culture waters (Shah et al. 2012), and sewage 
outfalls (Dolejska et al. 2011) are important 
sources, among others, leading to the pres­
ence of ARG in surface waters. In particu­
lar, the comparatively high concentrations of 
anti biotics found in the effluent of pharma­
ceuti cal production plants have been asso­
ciated with an increased presence of ARG 
in surface waters (Kristiansson et al. 2011; 
Li et al. 2009, 2010). Most recently, 100% 
sequence identity of ARG from a diverse set 
of clinical pathogens and common soil bacte­
ria (Forsberg et al. 2012) has highlighted the 
potential for environ mental HGT between 
eARB and pARB.
Despite these concerns, few risk assess­
ments have evaluated the combined impacts 
of anti biotics, ARG, and ARB in the environ­
ment on human and animal health (Keen and 
Montforts 2012). Recent epidemiological stud­
ies have included evaluation of ARB in drink­
ing water and the susceptibility of commensal 
Escherichia coli in household members. For 
example, Coleman et al. (2012) reported that 
water, along with other factors not directly 
related to the local environment, accounted for 
the presence of resistant E. coli in humans. In 
many studies, native bacteria in drinking water 
systems have been shown to accumulate ARG 
(Vaz­Moreira et al. 2011). 
In addition to addressing environmental 
risks arising from the development of anti­
biotic resistance, we should also consider the 
Figure 1. Conceptual model describing the environmental pathways that result in an increased risk of 
human and animal infection with antibiotic-resistant bacteria. Processes 1–6 are further described in the 
text. Because processes 7 and 8 are not driven by environmental factors, they are not discussed in detail. 
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low probability but high impact “one­time­
event” type of risk. This exceedingly rare 
event that results in the transfer of a novel (to 
clinically important bacteria) resistance gene 
from a harmless environmental bacterium to 
a pathogen need happen only once if a human 
is the recipient of the novel pARB. Unlike 
the emergence of SARS (severe acute respira­
tory syndrome) and similar viruses where, in 
hindsight, the risk factors are now well under­
stood (Swift et al. 2007), the conditions for 
a “one­time event” could occur in a range of 
“normal” habitats. Once developed, the resis­
tant bacterium/gene has a possibility to spread 
between humans around the world [such as 
seen with the spread of NDM­1 (New Delhi 
metallo­beta­lactamase­1) resistance (Wilson 
and Chen 2012)], promoted by our use of 
anti biotics. Although it seems very difficult to 
quantify the probability for such a rare event 
(including assessing the probability for where 
it will happen and when), there is consider­
able value in trying to identify the risk factors 
(such as pointing out critical environments for 
HGT to occur, or identifying pharmaceutical 
exposure levels that could cause selection pres­
sures and hence increase the abundance of a 
given gene). After such a critical HGT event, 
we may then move into a more quantitative 
kind of HHRA. 
The overall goal of the workshop (Anti­
microbial Resistance in the Environment: 
Asse s s ing  and Managing  Ef fec t s  o f 
Anthropogenic Activities) was to identify the 
significance of ARB within the environment 
and to map out some of the complexities 
involved in order to identify research gaps and 
provide statements on the level of scientific 
understanding of various ARB issues. A broad 
range of international delegates, including aca­
demics, government regulators, industry mem­
bers, and clinicians, discussed various issues. 
The focus of this review arose from discussions 
of improving our understanding of human 
health risks—in addition to epidemiological 
studies—by developing HHRAs to explore 
potential risks and inform risk manage ment. 
Because the end goal of an assessment depends 
on the context (e.g., research, regulation), we 
provide a generic approach to under taking an 
HHRA of environmental ARB that can be 
adapted to the users’ interest (conceptualized 
in Figure 1). Given the many uncertainties, we 
also highlight identified research gaps. 
General Considerations for an 
Assessment of Environmental 
ARB Risks
Understanding other on going relevant inter­
national activities and the types of anti biotics 
used provide good starting points to aid in 
framing a risk assessment of ARB. The Codex 
Alimentarius Commission (2011) described 
eight principles that are specific to risk analysis 
for foodborne anti microbial resistance, several 
of which are generally applicable to a HHRA 
of environ mental ARB. Examples include the 
recommendations of the Joint FAO/WHO/
OIE Expert Meeting on Critically Important 
Antimicrobials  (Food and Agriculture 
Organization of the United Nations/World 
Health Organization/World Organisation 
for Animal Health 2008) and the WHO 
Advisory Group on Integrated Surveillance 
of Antimicrobial Resistance (WHO 2012b), 
which provided information for setting the 
priority anti biotics for a human risk assess­
ment. It should be noted that there are sig­
nificant national and regional differences in 
anti biotic use, resistance patterns, and human 
exposure pathways.
In general, risk assessments are framed by 
identifying risks and management goals, so 
the assessment informs the need for possible 
management options and enables evaluation 
of management success. The consensus of 
workshop participants was that manage ment 
could best be applied at points of anti biotic 
manufacturing and use, agricultural operations 
including aquaculture, and wastewater treat­
ment plants (Pruden et al. 2013). Assessing 
the relative impact of managing any particular 
part of a system is hampered by the lack of 
knowledge on the relative importance of each 
part of the system for the overall risk. That 
is, as recently stated by the WHO (2013), 
“AMR is a complex problem driven by many 
inter connected factors so single, isolated 
interventions have little impact and coordi­
nated actions are required.” Hence, a start­
ing point for an assessment of environmental 
anti biotic­resistance risks intended to aid risk 
management is a theo retical risk assessment 
pathway based on a) local surveillance data on 
the occurrence and types of anti biotics used 
in human medi cine, crop production, animal 
husbandry, and companion animals; b) infor­
mation on ARG and ARB in the various 
environmental compartments (in particular, 
soil and aquatic systems including drinking 
water); and c) related disease information. This 
assessment should be amended by discussion 
with the relevant stakeholders, which requires 
extensive risk communication and could form 
part of the multi criteria decision analysis 
(MCDA) approach discussed in detail below. 
As a result of the workshop, Pruden et al. 
(2013) also advocate coupling environ mental 
manage ment and mitigation plans with tar­
geted surveillance and monitoring efforts in 
order to judge the relative impact and success 
of the interventions.
To undertake a useful human health risk 
assessment, some details require quantitative 
measures. Thus, the key issue is how experi­
mental and modeling approaches can be 
used to derive estimates. Furthermore, haz­
ard concentration, time, and environ mental 
compartment­dependent aspects should also 
be taken into account. First, the current 
understanding is that for non­mutation­
derived antibiotic resistance to develop in 
environmental bacteria (including pathogens 
that may actively grow outside of hosts) to 
develop into eARB/pARB (Figure 1, pro­
cesses 1 and 2), a selective pressure (i.e., pres­
ence of anti biotics or antibiotic­resistance 
determinants) must be maintained over 
time in the presence of ARG; for existing 
pARB released into the environment, sur­
vival in environmental media is the critical 
factor. However, the exact mechanisms and 
quantitative relationships between selective 
pressures and ARB development have yet 
to be elucidated, and they may be different 
depending on the anti biotic, bacterial spe­
cies, and resistance mechanisms involved. In 
cases where selective pressure is removed, the 
abundance of antibiotic­resistance ARB may 
be reduced, but not to extinction. (Andersson 
and Hughes 2010, 2011; Cottell et al. 2012). 
Even a small number of ARB at the com­
munity level represents a reservoir of ARG 
for horizontal transfer once pressure is reap­
plied. Because it seems inevitable that ARB 
will eventually develop against any anti biotic 
(Levy and Marshall 2004), the key manage­
ment aim seems to be to delay and confine 
such a development as much as possible.
Second, a robust quantitative risk assess­
ment will require rates of HGT and/or gene 
mutations in the relevant compartments 
(Figure 1, processes 3–5) to be described for 
different combinations of donating eARB 
strains and receiving pARB strains. The lack 
of quantitative estimates for mutation/HGT 
of ARG is a major data gap.
Third, traditional microbial risk assess­
ment dose–response approaches (Figure 1, 
processes 6 and 8) could be used to address the 
likeli hood of infection [Codex Alimentarius 
Commission 2011; U.S. EPA and U.S. 
Department of Agriculture/Food Safety and 
Inspection Service (USDA/FSIS) 2012], but 
the novel aspect required here—in addition 
to HGT and ARB selection—would be to 
address quantitative dose–response relation­
ships for eARB (in the presence of a sensitive 
pathogen in or on a human) (Figure 1, pro­
cesses 3 and 6). Importantly, the key difference 
from traditional HHRA undertaken in some 
jurisdictions is that it is essential to include 
environmental processes to fully assess human 
risks associated with anti biotic resistance.
Therefore, the type of information that 
should be documented for a human health–
oriented risk assessment of environmental ARB 
includes the following [adapted from Codex 
Alimentarius Commission (2011)]:
•	Clinical and environmental surveillance 
programs for anti biotics, ARB, and their 
determinants, with a focus on regional data 
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reporting the types and use of anti biotics in 
human medicine, crops, and commercial 
and companion animals, as well as globally 
where crops and food animals are produced
•	Epidemiological investigations of outbreaks 
and sporadic cases associated with ARB, 
including clinical studies on the occurrence, 
frequency, and severity of ARB infections
•	Identification of the selection pressures (time 
and dose of selecting/coselecting agents) 
required to select for resistance in differ­
ent environments, and subsequent HGT 
to human­relevant bacteria, both based on 
reports describing the frequency of HGT 
and uptake of ARG into environmental bac­
teria, including environmental pathogens, in 
previously identified hot spots 
•	Human, laboratory, and/or field animal/crop 
trials addressing the link between anti biotic 
use and resistance (particularly regional data)
•	Investigations of the characteristics of ARB 
and their determinants (ex situ and in situ)
•	Studies on the link between resistance, viru­
lence, and/or ecological fitness (e.g., surviv­
ability or adaptability) of ARB
•	Studies on the environmental fate of anti­
biotic residues in water and soil and their 
bioavailability associated with the selection 
of ARB in any given environmental com­
partment, animal, or human host result­
ing in pARB 
•	Existing risk assessments of ARB and related 
pathogens. 
In summary, many sources of data are 
required to undertake a human health risk 
assessment for environ mental ARB, and 
much of the data may be severely limited 
(particularly for a quantitative assessment). 
Thus, the final risk assessment report should 
emphasize the importance of the evidence 
trail and weight of evidence for each finding. 
Furthermore, when models are constructed, 
previously unused data sets should be consid­
ered for model verifications where possible.
Applicability of Traditional Risk 
Assessment Approaches
Human health risk assessment of anti biotics in 
the environment builds on traditional chemical 
risk assessments (National Research Council 
1983), starting, for example, with an accept­
able daily intake (ADI) based on resistance 
data (VICH Steering Committee 2012). A 
corresponding metric for environ mental anti­
biotic concentration could be developed based 
on the concept of the minimum selective 
concentration (MSC) (Gullberg et al. 2011), 
defined as the minimum concentration of 
an anti biotic agent that selects for resistance. 
Unlike the traditional chemical risk assess­
ment approach, with the MSC assay it would 
be necessary to address the human health 
effects arising from ARGs and the resistance 
determinants that give rise to ARB, including 
resistance associated with mutations (Figure 1, 
processes 1 and 2). In the absence of specific 
data, an MSC assay could inform a risk asses­
sor of the selective concentration of a pharma­
ceutical or complex mixture of compounds 
in a matrix of choice, allowing description of 
thresholds for significant ARB development. 
Pathogen risks may be evaluated through 
microbial risk assessment (MRA), a struc­
tured, systematic, science­based approach 
that builds on the chemical risk assessment 
paradigm; the MRA involves a) problem for­
mulation (describing the hazards, risk setting, 
and pathways), b) exposure assessment of the 
hazard (ARB, ARG), c) dose–response assess­
ment that quantifies the relationship between 
hazard dose and pARB infection in humans 
(Figure 1, processes 6 and 7), and d) com­
bination of these procedures to characterize 
risk for the various pathways of exposure to 
pathogens identified to be assessed. An MRA 
is used qualitatively or quantitatively to evalu­
ate the level of exposure and subsequent risk 
to human health from microbiological haz­
ards. In the context of anti biotic­resistant 
micro organisms, environmental MRA is in its 
infancy but is needed to address resistant bac­
teria and/or their determinants. The MRA was 
originally developed for fecal pathogen hazards 
in food and water [ILSI (International Life 
Sciences Institute) 1996], with more recent 
modifications to include biofilm­associated 
environmental pathogens such as Legionella 
pneumophila (Schoen and Ashbolt 2011). 
Some human pathogens can grow in the envi­
ronment (and may become pARB; Figure 1, 
processes 1 and 2), and many will infect only 
compromised individuals (generally termed 
opportunistic pathogens).
Over the past 20 years, the MRA has 
largely evolved by input from the inter­
national food safety community, and it is now 
a well­recognized and accepted approach for 
food safety risk analysis. In 1999, the Codex 
Alimentarius adopted the Principles and 
Guidelines for the Conduct of Microbiological 
Risk Assessment  (CAC/GL­30) (Codex 
Alimentarius Commission 2009). The most 
recent Codex Alimentarius guidelines for risk 
analysis of foodborne antimicrobial resistance 
include eight principles (Codex Alimentarius 
Commission 2011), and in the United States, 
MRA guidelines for food and water (U.S. 
EPA and USDA/FSIS 2012) continue to use 
the four­step framework originally described 
for chemical risk assessment. Several ARB risk 
assessments have been published and reviewed 
in recent years (Geenen et al. 2010; McEwen 
2012; Snary et al. 2004). However, nearly all 
of these studies focus on foodborne transmis­
sion; human health risk assessments dealing 
with ARB transmission via various environ­
mental routes or direct contact with ARG 
are sparse.
For example, Geenen et al. (2010) studied 
extended­spectrum beta­lactamase (ESBL)­
producing bacteria and identified the following 
risk factors: previous admission to health­care 
facilities, use of anti microbial drugs, travel to 
high­endemic countries, and having ESBL­
positive family members. The authors con­
cluded that an environ mental risk assessment 
would be helpful in addressing the problem of 
ESBL­producing bacteria but that none had 
been performed.
Hazard identification and hazard charac­
terization. Unfortunately, we are unaware of 
data that quantitatively link ARG uptake and 
human health effects (Figure 1, processes 3 
and 6). What data do exist and are rapidly 
improving in quality, however, are on the 
presence of ARGs within various environ­
mental compartments (Allen et al. 2009; 
Cummings et al. 2011; Ham et al. 2012), 
specifically on clinically rele vant resistance 
genes within soils (Forsberg et al. 2012) 
(Figure 1, process 1). Precursors that lead 
to the develop ment of ARB hazards include 
ARG and mecha nisms to mobilize these 
genes, anti biotics, and coselecting agents (Qiu 
et al. 2012; Taylor et al. 2011) along with 
gene mutations (Gillings and Stokes 2012). 
Depending on the presence of recipient bac­
teria, these processes generate either eARB or 
pARB (Figure 1, processes 1 and 2). 
In regard to the numerous parameters rele­
vant to individual environmental compart­
ments, we are not aware of the availability of 
comprehensive data on a) anti biotic resistance 
development by anti biotics and other coselect­
ing agents; b) the flow of ARG (resistome) 
and acquisition elements (e.g, integrons) in 
native environmental compartment bacteria; 
or c) the likely range in rates of horizontal and 
vertical gene transfer within environ mental 
compartments. Nonetheless, factors that are 
considered important include the range of 
potential pathways involving the release of 
anti biotics, ARG, and ARB into and amplify­
ing in environmental compartments such as 
the rhizosphere, bulk soil, compost, biofilms, 
wastewater lagoons, rivers, sedi ments, aqua­
culture, plants, birds, and wildlife.
With respect to anti biotics, in general, the 
following information is required to aid haz­
ard characterization: a) a list of the local anti­
biotic classes of concern, b) what is known of 
their environmental fate, and c) where they 
may accumulate, in particular, environmental 
compartments (e.g., the rhizosphere, general 
soil, compost, biofilms, wastewater lagoons, 
rivers, sediments, aquaculture, plants, birds, 
wildlife, farm animals, or companion ani­
mals). Selection for ARB (Figure 1, process 
2) will depend on the type and in situ bio­
availability of selecting/coselecting agents, the 
abundance of bacterial host, and the abun­
dance of AR determinants.
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Selection for ARB is further modulated by 
the nutritional status of members of the rele­
vant bacterial community because high meta­
bolic activity and high cell density promote 
bacterial community succession and HGT 
(Brandt et al. 2009; Sørensen et al. 2005). In 
contrast, HGT is relatively independent of 
anti biotics—although anti biotics and ARB 
may be co­transported (Chen et al. 2013)—
and increases in HGT rates are thought 
to occur in stressed bacteria. For example, 
integrase expression can be up­regulated 
(increased) by the bacterial SOS response 
(process for DNA repair) in the presence of 
certain anti biotics (Guerin et al. 2009). 
Although quantitative data that describe 
the development of pARB in the environment 
are lacking, ample evidence exists for the co­
uptake by an antibiotic­sensitive pathogen in 
the presence of an anti biotic, ARG (such as 
on a plasmid with metal resistance), and/or 
carbon utilization genes (Knapp et al. 2011; 
Laverde Gomez et al. 2011), or as demon­
strated in vitro for a disinfectant/nanomaterial 
(Qiu et al. 2012; Soumet et al. 2012). 
The spatial distribution of organisms 
(opportunity for close proximity) may also 
affect gene transfer, which results from inher­
ent patchi ness, soil structure, presence of 
substrates, and so forth. In considering gene 
transfer rates, there may be hot spots of activ­
ity; for example, there is evidence for HGT 
of clinically rele vant resistance genes between 
bacteria in manure­impacted soils (Forsberg 
et al. 2012) and in association with the rhi­
zosphere because of its organic­rich condi­
tions (Pontiroli et al. 2009). In addition, 
selection pressures for subsequent prolifera­
tion of eARB may be higher in these hot spot 
environments (Brandt et al. 2009; Li et al. 
2013). Therefore, it is important to reco gnize 
likely zones of high activity during the prob­
lem formulation and hazard characterization 
stages of a risk assessment, and when using 
sampling to identify in situ exchange rates. As 
an example marker of anthropogenic impact 
with potential to predict the impact on the 
mobile resistome, class 1 integrons could 
be used because of their ability to integrate 
gene cassettes that confer a wide range of 
anti biotic and biocide resistance (Gaze et al. 
2011). In semi­pristine soils, prevalence may 
be two or three orders of magnitude lower 
than in impacted soils and sedi ments (0.001 
vs. 1%, respectively) (Gaze et al. 2011; Zhu 
et al. 2013).
In addition to a huge diversity of eARB 
hazards, there are several pathogens that 
could be evaluated in microbial risk assess­
ments: a) foodborne and waterborne fecal 
pathogens represented by Campylobacter 
jejuni, Salmonella enterica, or various patho­
genic E. coli; and b) environ mental pathogens, 
such as respiratory, skin, or wound pathogens 
represented by Legionella pneumophila, 
Staphylococcus aureus, and Pseudomonas aeru-
ginosa. Each of these fecal and environmental 
pathogens is well known to be able to acquire 
ARG; thus, given further data on environmen­
tal HGT rates, they could be used as refer­
ence pathogens in microbial risk assessments. 
However, what is much more problematic 
for risk assessment—and a current limiting 
factor—is the rate at which the indigenous 
bacteria transfer resistance to these pathogens 
within each environmental compartment and 
within the human/animal host (Figure 1, pro­
cesses 3–5). Methods to model and experi­
mentally derive relevant information on these 
environmental issues are discussed below in 
“Environmental Exposure Assessment.” Data 
on HGT within the human gastro intestinal 
tract have been summarized by Hunter 
et al. (2008).
Dose–response relationships. To properly 
charac terize human risks, it is typical to select 
hazards for which there are dose–response 
health data described either deterministically 
or stochastically, as available for the refer­
ence enteric pathogens (e.g., Campylobacter 
jejuni, Salmonella enterica, E. coli) (Schoen 
and Ashbolt 2010), but these dose–response 
health data have yet to be quantified for the 
skin/wound reference pathogens (Mena and 
Gerba 2009; Rose and Haas 1999). However, 
as noted above for processes 1–5, (Figure 1), 
an important difference for ARB is the need 
to account for the phenomena associated 
with selective environmental pressures for 
the development of ARB, and ultimately that 
form the human infective dose of either eARB 
or pARB. The exact mechanisms and dose–
response relationships have yet to be eluci­
dated, and may be different depending on the 
bacterial species and resistance mechanisms 
involved. Nevertheless, it seems reasonable 
for the non compromised human exposed to 
a pARB to fit the published dose–response/
infection relationship (e.g., derived from 
“feeding” trials with healthy adults or from 
information collected during outbreak inves­
tigations) for strains of the same pathogen 
without antibiotic resistance. What appears 
more limiting are dose–response models that 
describe the probability of illness based on 
the conditional probability of infection and 
including people who are already compro­
mised, such as those under going anti biotic 
therapy. Although there is definitive data 
on pARB being more pathogenic or causing 
more severe illness than their antimicrobial­
susceptible equivalents (Barza 2002; Helms 
et al. 2004, 2005; Travers and Barza 2002), 
that may not always be the case (Evans 
et al. 2009; Wassenaar et al. 2007). Clear 
examples of excess mortality include associ­
ated blood stream infections for methicillin­
resistant Staphylococcus aureus (MRSA) and 
from third generation cephalosporin­resistant 
E. coli (G3CREC). In 2007 in participating 
European countries, 27,711 cases of MRSA 
were associated with 5,503 excess deaths and 
255,683 excess hospital days, and 15,183 epi­
sodes of G3CREC blood stream infections 
were responsible for 2,712 excess deaths 
and 120,065 extra hospital days (de Kraker 
et al. 2011). The authors predicted that the 
combined burden of resistance of MRSA 
and G3CREC will likely lead to a pre­
dicted incidence of 3.3 associated deaths per 
100,000 inhabitants in 2015. Yet for many 
regions of the world, such predictions are less 
well understood.
The final step of MRA is risk charac­
teriza tion, which integrates the outputs from 
the hazard identification, the hazard charac­
terization, dose response, and the exposure 
assessment with the intent to generate an 
overall estimate of the risk. This estimate may 
be expressed in various measures of risk, for 
example, in terms of individual or popula­
tion risk, or an estimate of annual risk based 
on exposure to specific hazard(s). Depending 
on the purpose of the risk assessment, the 
risk characterization can also include the 
key scientific assumptions used in the risk 
assessment, sources of variability and uncer­
tainty, and a scientific evalua tion of risk 
management options.
Environmental Exposure 
Assessment
Based on our conceptualization of the pro­
cesses important to undertake HHRA of ARB 
(Figure 1), most elements related to ARB 
development in environmental media (pro­
cesses 1, 2, and 4) have been addressed above 
in “Hazard identification and hazard charac­
terization.” Here we focus on describing 
important environmental compartments for 
and human exposure to ARB (Figure 1, pro­
cesses 3 and 6). Concentrations of environ­
mental factors (such as anti biotics) and ARB, 
along with their fate and transport to points 
of human uptake, are critical to exposure 
assessment. For a particular human health 
risk assessment of ARB, it would be impor­
tant to select/expand on individual pathway 
scenarios (identifying critical environmental 
compartments to human contact) relevant to 
the anti biotic/resistance determinants identi­
fied in the problem formulation and hazard 
characterization stages.
Compartments of potential concern 
include soil environments receiving animal 
manure or biosolids, compost, and lagoons, 
rivers, and their sediments receiving waste­
waters (Chen et al. 2013). More traditional 
routes of human exposures to contaminants 
that could include eARB and pARB are 
drinking water, recreational and irrigation 
waters impacted by sewage and/or anti biotic 
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production wastewaters, food, and air affected 
by farm buildings and exposure to farm ani­
mal manures, as discussed by Pruden et al. 
(2013). What is emerging as an important 
research gap is the in situ development of 
ARB within biofilms (Boehm et al. 2009) 
and their associated free­living protozoa that 
may protect and transport ARB (Abraham 
2010) to and within drinking water systems 
(Schwartz et al. 2003; Silva et al. 2008). This 
latter route could be particularly problem­
atic for hospital drinking water systems where 
an already vulnerable population is exposed. 
In addition, with the increasing use and 
exposure to domestically collected rainwa­
ter, atmospheric fallout of ARB may “seed” 
household systems (Kaushik et al. 2012).
After identifying anti biotic concentra­
tions and pathogen densities in the environ­
ment, as well as possible levels and rates of 
ARB generation in each environmental 
compartment, a range of fate and transport 
models are available to estimate the amounts 
of anti biotics, pathogens, ARB, and ARG 
at points of human contact (Figure 1, pro­
cesses 3 and 6). Such models are largely based 
on hydro dynamics, with pathogen­specific 
parameters to account for likely inactivation/
predation in soil and aquatic environments, 
such as sunlight inactiva tion (Bradford et al. 
2013; Cho et al. 2012; Ferguson et al. 2010). 
A key aspect of the fate and transport models 
is the ability to account for the inherent vari­
ability of any system component. In addition, 
our uncertainties in assessing model parameter 
values should be factored into fate and trans­
port models such as by using Bayesian syn­
thesis methods (Albert et al. 2008; Williams 
et al. 2011). To better account for param­
eter uncertainties, more recent models are 
including Bayesian learning algorithms that 
help to integrate information using meteo­
rologic, hydrologic, and microbial explana­
tory variables (Dotto et al. 2012; Motamarri 
and Boccelli 2012). Overall, these models also 
help to identify management opportunities to 
mitigate exposures to ARB and anti biotics and 
are an important aspect in describing the path­
ways of hazards to points of human exposure 
in any risk assessment.
MCDA and Risk Ranking 
Methods
Considering the complexity of exposure path­
ways associated with environmental ARB risks 
and the large uncertainty in the input data for 
some nodes along the various exposure path­
ways, outputs would inevitably be difficult for 
decision makers to interpret and could in fact 
be counter productive. Thus, there is merit 
in considering decision analysis approaches 
to prioritize risks, guide resource allocation 
and data collection activities, and facilitate 
decision making. Although there is a range 
of ranking options, uses of weightings, and 
selection criteria (Cooper et al. 2008; Pires 
and Hald 2010), as well as failure mode and 
effects analysis (Pillay and Wang 2003), in 
the overall area of microbial risk assessment, 
there is a consolidation to MCDA approaches 
that may include Bayesian algorithms (Lienert 
et al. 2011; Ludwig et al. 2013; Ruzante 
et al. 2010). 
Approaches such as MCDA are designed 
to provide a structured framework for mak­
ing choices where multiple factors need to 
be considered in the decision­making pro­
cess. MCDA is a well­established tool that 
can be used for evaluating and document­
ing the importance assigned to different fac­
tors in ranking risks (Lienert et al. 2011), 
albeit heavily dependent on expert opinion. 
In the context of MRA, MCDA has been 
used to rank foodborne microbial risks based 
on multiple factors, including public health, 
market impacts, consumer perception and 
acceptance, and social sensitivity (Ruzante 
et al. 2010), as well as to prioritize and select 
inter ventions to reduce pathogen exposures 
(Fazil et al. 2008). Examples of MCDA 
applications in structuring decisions for man­
aging eco toxico logi cal risks have also been 
reported (Linkov et al. 2006; Semenzin et al. 
2008) and provide useful MCDA approaches. 
MCDA could be used, for example, to evalu­
ate and rank the relative risks between habi­
tats highly polluted with anti biotics, ARG, 
and ARG determinants, as described above 
for possible hot spots for HGT and develop­
ment of ARB. MCDA could be applied to 
evaluate the relative contribution of coselect­
ing agents (e.g., detergents, biocides, met­
als, nano materials) from various sources to 
the overall risk of ARB in the environment. 
Moreover, for a range of anti biotics consid­
ered to be of environmental concern, MCDA 
approaches could be used for risk ranking 
according to criteria based on relevant con­
tributing factors (e.g., mobility of resistance 
determinants in genetic elements, antibiotic­
resistance transfer rates in different environ­
mental compartments, accumulation levels of 
anti biotics in environmental compartments, 
environmental fate and transport to expo­
sure points). In the MCDA process, it is also 
important to identify low probability but 
high impact “one­time­event” types of risk. 
Because MCDA techniques rely on expert 
opinion (which is often regarded as a limi­
tation of such approaches), well­structured 
and recognized elicitation practices should be 
used in order to avoid introduction of biases 
and errors by subjective scoring. In contrast, 
one of the main advantages of MCDA tech­
niques is that they capture a consensus opin­
ion among an expert group about the most 
relevant criteria and their relative weight on 
the decision.
Important Research Gaps 
Affecting Progress of HHRA 
of Anti biotic Resistance 
There are several research gaps that need to 
be addressed. In particular, specific atten­
tion should be paid to contaminated habitats 
(hot spots) in which anti biotics, coselecting 
agents, bacteria carrying resistance determi­
nants on mobile genetic elements, and favor­
able conditions for bacterial growth and 
activity—all conditions expected to favor 
HGT—prevail at the same time. However, 
because these data are currently very limited, 
workshop participants evaluated alternative 
ways and possible experimental methods to 
address these data gaps for HHRA as they 
relate to the processes identified in Figure 1. 
Assays to determine MSC (processes 1, 2, 
and 4). Assays could be developed to mea­
sure MSC (Gullberg et al. 2011) for a range 
of anti biotics and environmental conditions. 
For example, assays could be developed and 
validated in sandy and clay soils, different 
sediments, and water types, with isogenic 
pairs of the model organism inoculated into 
the matrix of choice and subjected to a titra­
tion of the selective agent to sufficiently high 
dilution. Selection at sub inhibitory concen­
trations and assay development for environ­
mental matrices are key areas of research that 
need to be addressed. However, overall care is 
needed when interpreting ex situ studies and 
extrapolating to in situ environmental condi­
tions, as well as in dealing with ill­defined 
hazard mixtures in the environment. 
Assays to identify environmental hot spots 
(processes 1, 2, and 4). Hot spots, locations 
where a high­level of HGT and anti biotic 
resistance develop, may, for instance, include 
aquatic environments affected by pharma­
ceutical industry effluents, aqua culture, or 
sewage discharges, as well as terrestrial 
environments affected by the deposition of 
biosolids or animal manures. The degree of 
persistence of anti biotic resistance (i.e., the 
rate by which resistance disappears without 
having an environ mental selection pressure 
for resistance) must also be considered for 
risk assessment and will depend on the fit­
ness cost of resistance. However, the fitness 
costs within complex and variable environ­
ments are difficult to assess. Furthermore, 
standard methods have not been developed 
for evaluating environ mental selection pres­
sures in complex microbial communities, but 
several experimental approaches are possible 
and have been described elsewhere (Berg et al. 
2010; Brandt et al. 2009).
The approaches identified by Berg et al. 
(2010) and Brandt et al. (2009) could be 
labo ra tory based (to assess the potency of 
known compounds/mixtures) or applied in 
the field to assess whether the environment 
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in question (with, for example, its unknown 
mixture of chemicals) is a hot spot. Defining 
“critical exposure levels” is therefore an 
important HHRA output to aid manage­
ment activities, which will likely vary between 
and within environmental compartments, 
depending on the location.
Screening for novel resistance determinants 
(to reduce process 2). Screening procedures 
could be introduced early in the development 
cycle of novel anti biotics to ensure that exist­
ing resistance determinants are not prevalent 
in environmental compartments. Marked 
recipient strains could be inoculated into 
environmental matrices [e.g., soil, biosolids, 
or fecal slurry (with sterilized matrix equiva­
lents as negative controls)], incubated, and 
then seeded onto media containing the study 
compound along with a selective anti biotic to 
recover marked recipient strains demon strating 
resistance. Plasmids, or the entire genome of 
the recipient, could then be cloned into small 
insert expression vectors, transformed into 
E. coli or other hosts, and seeded back onto 
media containing the study compound. In 
this way, novel resistance determinants would 
be identified.
Alternatively, functional meta genomics 
could be used to identify novel resistance 
determinants in meta genomic DNA (Allen 
et al. 2009). In brief, DNA would be 
extracted from an environmental sample, 
cloned into an expression vector, and trans­
formed into a bacterial host such as E. coli. 
Transformants could then be screened on the 
study compound and resistance genes identi­
fied using transposon muta genesis followed 
by sequencing and bio informatic analyses. 
This would allow detection of novel resistance 
determinants that may not be plasmid borne 
but may transfer to other pathogens.
Dose–response data needs (processes 3, 5, 
and 6). We were unaware of dose–response 
data representing a combined ARG and a 
recipient, previously susceptible pathogen 
dose, and human or animal disease (Figure 1, 
processes 3 and 5). In contrast, various exam­
ples illustrate increased morbidity and mor­
tality when humans are exposed to pARB, 
as described above in “Dose–response rela­
tionships.” Hence, existing published dose–
response models for non resistant pathogens 
(Haas et al. 1999) may not be appropriate 
to use beyond the end point of infection, 
and further dose–response models that 
address people of various life­stages need to 
be described and summarized to facilitate 
pARB risk assessments. There is also a need 
to develop dose–response information for sec­
ondary illness end points (sequelae) resulting 
from pARB infections.
Regarding anti biotic concentration and 
time of exposure giving rise to selection of 
pARB within a human (for co­uptake of 
eARB and a sensitive pathogen), safety could 
be based on the effective concentration for 
the specific anti biotic under consideration. In 
other words, screening values to determine 
whether further action is warranted could be 
derived from the acute or mean daily anti­
biotic intake, with uncertainty factors applied 
as appropriate, until future research is under­
taken on pathogen anti biotic­response changes 
in the presence of specific anti biotic treatment. 
Alternatively, epidemiological data from exist­
ing clones of anti biotic­resistant strains (e.g., 
NDM­1) could provide useful data for dose–
response and exposure assessments.
Options for ranking risks (overall HHRA). 
In the absence of fully quantitative data to 
undertake a HHRA, risk­ranking approaches 
based on exposure assessment modeling could 
be adopted and developed to inform allocation 
of resources for data generation as part of an 
HHRA of ARB. Evers et al. (2008) presented 
one such approach in the context of food 
safety for estimating the relative contribution 
of Campylobacter spp. sources and transmis­
sion routes on exposure per person­day in the 
Netherlands. Their study included 31 transmis­
sion routes related to direct contact with animals 
and ingestion of food and water, and resulted 
in a ranking of the most significant sources 
of exposure. Although their study focused on 
foodborne transmission routes and did not deal 
with anti biotic­resistant Campylobacter strains, 
a similar approach could be applied to estimate 
human exposure to ARB hazards using the 
environmental exposure pathways described by 
Evers et al. (2008). This would require data on 
the prevalence of ARG and ARB, as well as lev­
els of anti biotics present in all exposure routes to 
be considered in the risk assessment. Although 
such an approach is probably not currently fea­
sible, improved environmental data for a select 
number of pathogen–gene combinations could 
be developed in the future.
An alternative approach to capturing 
knowledge of experts and other stakeholders 
could be to develop a Bayesian network based 
on expert knowledge and add to that as data 
become available, as described for campylo­
bacters in foods by Albert et al. (2008).
Conclusions
Because we are addressing an inter national 
problem and because the precautionary 
approach is used in many jurisdictions, there 
are many risk management approaches that 
can be implemented now, before anti biotic­
resistance issues worsen, as noted in the related 
risk management paper resulting from the 
workshop (Pruden et al. 2013). Furthermore, 
many current risk management schemes start 
the process from a management perspec­
tive and delve into quantitative assessments 
as needed in order to improve risk manage­
ment actions, such as in the WHO water 
safety plans (WHO 2009). We propose that 
environmental aspects of anti biotic­resistance 
development be included in the processes of 
any HHRA addressing ARB. In general terms, 
an MRA appears suitable to address environ­
mental human health risks posed by the envi­
ronmental release of anti biotics, ARB, and 
ARG; however, at present, there are still too 
many data gaps to realize that goal. Further 
development of this type of approach requires 
data mining from previous epidemiological 
studies to aid in model development, param­
eterization, and validation, as well as in the 
collection of new information, particularly 
that related to conditions and rates of ARB 
development in various hot spot environ­
ments, and for various human health dose–
response unknowns identified in this review. 
In the near­term, options likely to provide a 
first­pass assessment of risks seem likely to be 
based on MCDA approaches, which could be 
facilitated by Bayesian network models. Once 
these MRA models gain more acceptance, 
they may facilitate scenario testing to deter­
mine which control points may be most effec­
tive in reducing risks and which risk­driving 
attributes should be specifically considered 
and minimized during the development of 
novel anti biotics. 
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